In adults who had not had COVID-19, Novavax vaccine had 90% efficacy at ≥7 d after the second dose
- PMID: 35500261
- DOI: 10.7326/J22-0028
In adults who had not had COVID-19, Novavax vaccine had 90% efficacy at ≥7 d after the second dose
Abstract
Dunkle LM, Kotloff KL, Gay CL, et al. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. N Engl J Med. 2022;386:531-43. 34910859.
Comment on
-
Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico.N Engl J Med. 2022 Feb 10;386(6):531-543. doi: 10.1056/NEJMoa2116185. Epub 2021 Dec 15. N Engl J Med. 2022. PMID: 34910859 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical